Entheias Biosciences is developing a patent-protected therapeutic vaccine platform designed to convert non-responders into responders, unlocking functional cure for the patients who need it most.
See the opportunityThe HBV field has converged on combination therapy as the path to cure. Therapeutic vaccination is the critical immune-activating component, but published clinical data show that approximately 40% of patients fail to respond to current therapeutic vaccine approaches.
This non-responder population remains entirely unaddressed. Every vaccine candidate in the global pipeline shares the same mechanistic limitation.
No program in the global pipeline targets the root cause of therapeutic vaccine failure in this population. The mechanistic gap is well-defined, the patient population is large, and the combination backbone needed to achieve cure is rapidly maturing.
Entheias has developed a patent-protected platform that addresses this specific gap through a novel immunological mechanism with no direct competitor.
Addresses the root cause of non-responder failure through an immunological approach fundamentally distinct from all existing therapeutic vaccine candidates.
Built on a biological principle demonstrated in vivo in analogous therapeutic contexts, including cancer immunotherapy, where it generated functional immune responses.
Complementary MOA designed for synergistic use with the emerging cure backbone. Not competitive with existing approaches, additive to them.
Entheias is seeking a strategic development partner to advance its patent-protected platform from preclinical proof-of-concept through clinical development. Scientific rationale and mechanism disclosure available under NDA.
fightingforcure@entheias.com